Member Info for RayPointer

Recruitment completed for covidity is nice to see

My bet is that she's busy negotiating another Glymab deal or possibly an Avidimab deal.

Very well said crumbs and I agree totally

It's crackin' logic

That bodes well for trial results :-)

That long association is quite fascinating, crumbs.
It looks like Lindy has had a long interest in glycans as targets.

https://www.scancell.co.uk/anti-glycan-mab

3 out of the 5 Glycans mAbs target Lewis glycans.

"SC129: specific for the sialyl-di-Lewisa glycan, a target for pancreatic cancer
SC134: specific for fucosyl GM1, a target for small cell lung cancer
SC88: specific for the Lewisacx glycan, a target for colorectal cancer
SC27: specific for the Lewisy glycan, a target for gastric cancer
SC2811: specific for SSEA4 on human and mouse T cells with stem-like properties – a target for any solid tumour"

So, at some point, Lindy must have started research with the help of PhD students. A few years ago, the research was obviously advanced enough for it to be transferred to Scancell. Then Lindy had the setback of the mAbs losing their cancer cell killing potential when humanised. Not to be deterred she isolated what the problem was and hence Avidimab was born.

So, after more research, Lindy calls her old mate at Genmab "Anders, I've cracked it!"
Anders then starts searching for the company chequebook.

The previous paragraph is pure FANTASY :-)

MY CAPS LOCK IS STUCK ON AS WELL

Hi Jamboian
I was having very similar thoughts.
It seems as though, in the current climate, many investors are just not parting with their cash. Those that are parting with cash are looking for short term profits.
It may need a second deal to ignite the SP. Either that or positive data from the trials.

Eee, we used to dream about having plastic sheeting

https://www.bing.com/videos/search?q=four+yorkshiremen+youtube&view=detail&mid=DD060CA70BE85FC47749DD060CA70BE85FC47749&FORM=VIRE0&ru=%2fsearch%3fq%3dfour%2byorkshiremen%2byoutube%26qs%3dLT%26pq%3dfour%2byorkshiremen%2byou%26sc%3d6-21%26cvid%3d898D68E6F8F442758E1D0C1831771AC8%26FORM%3dQBRE%26sp%3d7

As long as the upfront payment is enough to buy the reinforced cardboard to keep Lindy and her team working through the Winter.

It does seem to be a deal for just 1 of the Glycans mAbs.

"Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces a licensing agreement with Genmab (NASDAQ: GMAB), an international biotechnology company, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products."

The mAb can be used in different ways

1 Just with Avidimab
2 Avidimab with an ADC
3 To mediate a CarT cell attack
4 As a bispecific mAb to mediate at conventional T Cell attack

As I understand it, number 4 is being taken into the clinic by Scancell

Morning krafty

This deal could trigger a major rerate over the coming weeks and months. IMO we could soon see more deals for the Glymab or Avidimab platforms. Lindy did say that Scancell had turned down two deals so deal number two could be just around the corner. Scancell have 4 collaborators and 5 Glycans mAbs!
Further down the line the Avidimab poster did mention the possibility of assessing Avidimab attached to checkpoint inhibitors. Imagine the market if these assessments catch the eye of big pharma.
Allied to that, Scancell have 3 trials of their own in progress.
It's tempting to say that the floodgates have been opened :-)

https://www.genmab.com/pipeline/

Lots of scope for Avidimab I would have thought

TF
You will see that the guy on the youtube posted by Bermuda specifically rubbishes JC's view on aspriration.
This was along with JC's incorrect conclusions on death certificate statistics, and also not knowing that an abstract at a conference is not necessarily linked to a published study with data.
Quite damning really but good luck to JC, he is obviously making a lot of money spouting incorrect conclusions.
A PHD in nursing and it shows :-)

I am keeping warm in Southern Italy at the present :-)

Bojo is good at fracking, so it is rumoured

Hi Chester
I may have missed something here but I don't think Seagen are using Avidimab in a clinical trial.
My understanding is that Scancell are performing pre clinical work on one of their products and the results were presented as a poster at the recent Euromab conference.
ATB

Hi Johnny

But rather than speculating, we are best just awaiting an RNS from Scancell.
I would suspect that all the safety and toxicity tests are being done at the 3 centres that are recruiting. Once these hurdles are overcome then they may open other centres.
All IMO.

https://www.clinicaltrials.gov/ct2/show/NCT05329532#contacts

According to the clinical trials register, the Royal Marsden are not yet recruiting

I thought the show was over when Boris resigned but it looks like it was only an interval.